Details

Autor(en) / Beteiligte

• Inoue, Yuichi
• Hirata, Koichi
• Hayashida, Kenichi
• Hattori, Nobutaka
• Tomida, Takayuki
• Garcia-Borreguero, Diego

Titel

Efficacy, safety and risk of augmentation of rotigotine for treating restless legs syndrome

Ist Teil von

• Progress in neuro-psychopharmacology & biological psychiatry, 2013-01, Vol.40, p.326-333

Ort / Verlag

Amsterdam: Elsevier Inc

Erscheinungsjahr

2013

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The present study aimed to examine the long-term efficacy and safety of rotigotine treatment for restless legs syndrome (RLS), as well as the rate of clinically significant augmentation, in a 1-year open-label study of Japanese subjects. Japanese patients with RLS who had been treated with rotigotine or placebo in a double-blind trial were enrolled in a 1-year, open-label, uncontrolled extension study and treated with rotigotine at a dose of up to 3mg/24h after an 8-week titration phase. Outcomes included International Restless Legs Syndrome Study Group rating scale (IRLS scale), Pittsburgh Sleep Quality Index (PSQI), safety, and investigator-/expert panel-assessed augmentation (including Augmentation Severity Rating Scale). Overall, 185 patients entered the open-label study and 133 completed the study. IRLS and PSQI total scores improved throughout the 52-week treatment period (IRLS, from 23.2±5.1 to 7.8±7.6 and PSQI, from 8.0±3.1 to 5.0±2.9). Treatment-emergent adverse events were mild to moderate in severity, and included application site reactions (52.4%) and nausea (28.6%). Clinically significant augmentation occurred in five patients (2.7%). These results indicate a good long-term efficacy of rotigotine for treating RLS, with a relatively low risk of clinically significant augmentation. ► Rotigotine shows good efficacy and safety in patients with restless legs syndrome. ► Rotigotine at up to 3mg/24h significantly improved IRLS, PSQI and SF-36 scores. ► Mean IRLS scores decreased from 23.2 to 7.8 during the 52-week study period. ► Clinically significant augmentation occurred in five patients (2.7%). ► Rotigotine was well tolerated with adverse events of only mild to moderate severity.